<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02847286</url>
  </required_header>
  <id_info>
    <org_study_id>IPM 036</org_study_id>
    <nct_id>NCT02847286</nct_id>
  </id_info>
  <brief_title>To Assess the Drug-drug Interaction Potential Between Dapivirine Vaginal Ring-004, Containing 25 mg of Dapivirine, and Clotrimazole 10 mg/g (1%)</brief_title>
  <official_title>AN OPEN-LABEL, RANDOMISED TRIAL, WITH A THREE-PERIOD CROSSOVER PART IN HEALTHY HIV-NEGATIVE WOMEN TO ASSESS THE DRUG-DRUG INTERACTION POTENTIAL BETWEEN DAPIVIRINE VAGINAL RING-004, CONTAINING 25 MG OF DAPIVIRINE, AND CLOTRIMAZOLE 10 mg/g (1%) ADMINISTERED AS A VAGINAL CREAM, WITH A FOLLOW-ON PERIOD TO ASSESS THE EFFECT OF MULTIPLE RING REMOVALS AND RE-INSERTIONS DURING THE 28-DAY PERIOD OF THE DAPIVIRINE VAGINAL RING-004 USE ON THE SYSTEMIC AND LOCAL EXPOSURE AND RESIDUAL AMOUNT OF DAPIVIRINE IN USED RINGS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to assess the drug-drug interaction potential, between Dapivirine Vaginal Ring-004,
      containing 25 MG of Dapivirine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AN OPEN-LABEL, RANDOMISED TRIAL, WITH A THREE-PERIOD CROSSOVER PART IN HEALTHY HIV-NEGATIVE
      WOMEN TO ASSESS THE DRUG-DRUG INTERACTION POTENTIAL BETWEEN DAPIVIRINE VAGINAL RING-004,
      CONTAINING 25 MG OF DAPIVIRINE, AND CLOTRIMAZOLE 10 mg/g (1%) ADMINISTERED AS A VAGINAL
      CREAM, WITH A FOLLOW-ON PERIOD TO ASSESS THE EFFECT OF MULTIPLE RING REMOVALS AND
      RE-INSERTIONS DURING THE 28-DAY PERIOD OF THE DAPIVIRINE VAGINAL RING-004 USE ON THE SYSTEMIC
      AND LOCAL EXPOSURE AND RESIDUAL AMOUNT OF DAPIVIRINE IN USED RINGS
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Actual">November 28, 2016</completion_date>
  <primary_completion_date type="Actual">November 28, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dapivirine concentrations in plasma</measure>
    <time_frame>28-day</time_frame>
    <description>Dapivirine concentrations in plasma, measured at specified time points during each 28-day period that the ring is inserted, and for 14 days following ring removal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clotrimazole concentrations in plasma</measure>
    <time_frame>7 days of once daily dosing, and for 14 days after the last administration</time_frame>
    <description>Clotrimazole concentrations in plasma, measured at specified time points during 7 days of once daily dosing, and for 14 days after the last administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dapivirine concentrations in vaginal fluid</measure>
    <time_frame>28 days</time_frame>
    <description>Dapivirine concentrations in vaginal fluid, collected at the cervix, measured at specified time points during each 28-day period that the ring is inserted, and for three days following ring removal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clotrimazole concentrations in vaginal fluid</measure>
    <time_frame>7 days of once daily dosing, and following 14 days after the last administration.</time_frame>
    <description>Clotrimazole concentrations in vaginal fluid, measured at specified time points during 7 days of once daily dosing, and following 14 days after the last administration.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>HIV- Prevention</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapivirine Ring-004 for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clotrimazole, 5 g per day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine Ring-004</intervention_name>
    <description>Treatment A: Dapivirine Ring-004 for 28 days</description>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Treatment A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine Ring-004 for 28 days along with clotrimazole</intervention_name>
    <description>Treatment B: Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days</description>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Treatment B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole</intervention_name>
    <description>Treatment C: Clotrimazole, 5 g per day for 7 days</description>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>Treatment C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must meet all the following criteria to be eligible to enrol in the trial:

          1. Women 18 and â‰¤ 45 years of age who can give written informed consent

          2. Available for all visits and consent to follow all procedures scheduled for the trial

          3. Healthy, based on medical history, vital signs, physical examination, urinalysis
             (dipstick and microscopy), laboratory evaluations for genital infections (bacterial
             vaginosis, gonorrhoea, chlamydia and trichomonas), and laboratory evaluations for
             haematology and chemistry

          4. HIV-negative as determined by an HIV test at the time of screening

          5. On a stable form of contraception, defined as:

        A stable oral contraceptive regimen for at least 2 months prior to enrolment, OR
        Transdermal contraceptive patch for at least 3 months prior to enrolment, OR Long-acting
        progestins for at least 6 months prior to enrolment, OR An intra-uterine device (IUD)
        inserted (with no vaginal or gynaecological complaints associated with its use) at least 3
        months prior to enrolment, OR Have undergone surgical sterilisation at least 3 months prior
        to enrolment, AND willing to use oral contraceptives if necessary to delay menstruation
        during the vaginal sampling period 6. Upon pelvic examination at the time of enrolment, the
        cervix and vagina appear normal as determined by the Investigator/Physician Asymptomatic
        for genital infections at the time of enrolment (if a woman is diagnosed with any treatable
        STI, either clinically or by laboratory test at the time of screening, she must complete
        treatment prior to enrolment) 8. Willing to refrain from the use of topical vaginal
        medications, vaginal products or objects, including female condoms, tampons, cotton wool,
        rags, diaphragms, cervical caps (or any other vaginal barrier method), douches, lubricants,
        vibrators/dildos, and drying agents for 14 days prior to enrolment and for the duration of
        the trial 9. Documentation of no abnormality on cervical cytology, including grossly bloody
        smear, within 90 days prior to screening 10. Willing to refrain from participation in any
        other research trial for the duration of this trial 11. Willing to provide adequate locator
        information for trial retention purposes and be reachable per local standard procedures,
        e.g. by home visit or telephone, or via family or close neighbour contacts (confidentiality
        to be maintained) 12. Willing to agree to abstain for a total of 2 days (48 hours) prior to
        each trial visit from: Penile-vaginal intercourse Oral contact with her genitalia 13.
        Hepatitis B and C negative at the time of screening

        Exclusion Criteria:

        Participants who have any of the following criteria are NOT eligible to enrol in the trial:

          1. Currently pregnant or had their last pregnancy outcome within 3 months prior to
             screening

          2. Currently breast-feeding

          3. Currently or within 2 months of participation in any other clinical research trial
             involving investigational or marketed products prior to screening

          4. Untreated symptomatic urogenital infections, e.g. urinary tract or other STIs, or
             other gynaecological conditions such as vaginal itching, pain, or discharge within 14
             days prior to enrolment

          5. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,
             urethral obstruction, incontinence, urge incontinence or an anatomical variation that
             will not allow placement or retention of the ring

          6. Current vulvar or vaginal symptoms/abnormalities that could influence the trial
             results

          7. Cervical cytology at screening that requires cryotherapy, biopsy, treatment (other
             than for infection), or further evaluation

          8. Symptomatic genital herpes simplex virus (HSV) infection or a history of genital
             herpetic infection

          9. Any Grade 2, 3 or 4 haematology, biochemistry or urinalysis laboratory abnormality at
             baseline (screening) according to the Division of Acquired Immunodeficiency Syndrome
             (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events; Addendum
             1 Female Genital Grading Table for Use in Microbicide Studies

         10. Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or
             gynaecologic surgery within 90 days prior to enrolment

         11. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of
             sensitivity/allergy to latex or silicone

         12. Any serious acute, chronic or progressive disease (e.g. any known history of neoplasm,
             cancer, diabetes, epilepsy, cardiac disease, autoimmune disease, HIV, Acquired
             Immunodeficiency Syndrome [AIDS], or blood dyscrasias), or signs of cardiac disease,
             renal failure, or severe malnutrition

         13. Have undergone a hysterectomy

         14. Any condition(s) that, in the opinion of the Investigator, might interfere with
             adherence to trial requirements or evaluation of the trial objectives.

             Participants who have the following criterion are NOT eligible for Treatment F:

         15. Using a hormonal intrauterine device.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

